Table 2:

ART, adherence and psychosocial characteristics of the sample (n=527):

	N	%

VAS, categorical
0 – 50 %	98	18.6
51 – 60 %	18	3.4
61 – 70 %	58	11.0
71 – 80 %	206	39.1
81 – 90%	147	27.9
ART regimen
Zidovudine + Lamivudine + Nevirapine	257	48.8
Tenofovir + Lamivudine + Efavirenz	179	34.0
Other 2 NRTI + 1 NNRTI combination	82	15.6
Protease inhibitors	9	1.7
Detectable viral load (≥ 100 copies/ml), n=526	277	52.7
Any social support to remember to take ART	439	83.3
At least moderately depressed (PHQ ≥ 10), n = 526	63	12.0
Disclosed to all adult household members, n=524	433	82.6

	Mean	SD

VAS	68.1	24.6
Time on ART, in months	45.2	34.2
No. of perceived side effects of ART (0 – 17)	3.9	3.6
No. of perceived benefits ART (0 – 13)	10.2	3.7
Internalized stigma(0 – 3)	0.9	0.7
Stigma fears re. family (0 – 3)	0.9	1.0
Stigma fears re. friends (0 – 3)	2.3	1.0
Stigma fears re. people at work (0 – 3)	1.3 / 1.7 ^a	1.3 /1.3^a
Stigma fears re. HCW (0 – 3)	0.9 / 1.1^b	1.2 / 1.2^b
Stigma fears re. community members (0 – 3)	1.4 /	1.0
Avoidant coping index (0 – 15)	4.4	2.6
No. of individual adherence barriers (0 – 7)	2.5	1.2
No. of family adherence barriers (0 – 3)	0.3	0.5
No. of clinic and regimen adherence barriers (0 – 9)	1.4	1.1
No. of social and structural adherence barriers (0 – 7)	1.5	1.0
No. of clinic-attendance barriers (0 – 4)	0.7	1.0
No. of adherence strategies used (0 – 13)	4.1	1.6

HCW, health care workers; NRTI, Nucleoside Reverse Transcriptase Inhibitor; NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitor

First result is based on all participants; those not-employed scored 0. Second result is based on employed participants (n=396) only.

First result is based on all participants; those who had disclosed to all HCW scored 0. Second result is based on only participants who had not fully disclosed to HCW (n=411).